...
首页> 外文期刊>Clinical chemistry and laboratory medicine: CCLM >Evaluation of four commercial biuret reagent kits of serum total protein by the American Association for Clinical Chemistry reference measurement procedure.
【24h】

Evaluation of four commercial biuret reagent kits of serum total protein by the American Association for Clinical Chemistry reference measurement procedure.

机译:通过美国临床化学协会参考测量程序评估四种市售缩二脲试剂盒的血清总蛋白。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

BACKGROUND: In China, the traceability of clinical chemistry methods is still immature. Therefore, it is necessary to establish a reference measurement procedure and evaluate commercial reagent kits using such established procedures. METHODS: We reproduced the reference measurement procedure for serum total protein, as recommended by the American Association for Clinical Chemistry (AACC). We evaluated the performance by Clinical Laboratory Standard Institute (CLSI) guidelines EP15-A and EP6-A. Subsequently, four commercial reagent kits were evaluated by the reproduced reference procedure following CLSI guideline EP9-A2. RESULTS: The performance of the reproduced reference procedure was as follows: CVs ranged from 0.47% to 0.85% at medical decision levels (X(c)) of 45 g/L, 60 g/L and 80 g/L. Linearity was Y=1.0022X-0.2121 (r=0.9999), and recovery ranged from 100.2% to 102.4%. The External Quality Assessment Scheme for Reference Laboratories in Laboratory Medicine (RELA) was applied, and the result was within the limit of equivalence. The linear relationships of four commercial reagent kits, Merit Choice, KHB, Leadman, and Olympus, were, respectively: Y=0.9922X+0.5776 (r=0.9961); Y=0.9936X+0.4316 (r=0.9992); Y=0.9949X+0.9129 (r=0.9987) and Y=0.9923X+0.8876 (r=0.9989). KHB showed slight negative bias, and the mean+/-SD was -0.03+/-0.60 g/L. Merit Choice, Leadman, and Olympus all showed positive bias, and the mean+/-SDs were 0.02+/-0.63 g/L, 0.55+/-0.77 g/L and 0.34+/-0.71 g/L, respectively. CONCLUSIONS: The correlation and bias of four commercial reagent kits for serum total protein were found to be acceptable. Thus, these reagent kits can be used reliably in China.
机译:背景:在中国,临床化学方法的可追溯性仍不成熟。因此,有必要建立参考测量程序并使用这种已建立的程序评估商用试剂盒。方法:我们复制了美国临床化学协会(AACC)推荐的血清总蛋白的参考测量程序。我们根据临床实验室标准协会(CLSI)指南EP15-A和EP6-A评估了性能。随后,按照CLSI指南EP9-A2,通过复制的参考程序评估了四个商用试剂盒。结果:复制参考程序的性能如下:在医学决策水平(X(c))为45 g / L,60 g / L和80 g / L的情况下,CV在0.47%至0.85%之间。线性为Y = 1.0022X-0.2121(r = 0.9999),回收率范围为100.2%至102.4%。应用了实验室医学参考实验室的外部质量评估计划(RELA),其结果在等效范围内。四种商品试剂盒,Merit Choice,KHB,Leadman和Olympus的线性关系分别为:Y = 0.9922X + 0.5776(r = 0.9961); Y = 0.9936X + 0.4316(r = 0.9992); Y = 0.9949X + 0.9129(r = 0.9987)和Y = 0.9923X + 0.8876(r = 0.9989)。 KHB表现出轻微的负偏差,平均值+/- SD为-0.03 +/- 0.60 g / L。 Merit Choice,Leadman和Olympus均显示出正偏差,平均值+/- SDs分别为0.02 +/- 0.63 g / L,0.55 +/- 0.77 g / L和0.34 +/- 0.71 g / L。结论:发现四种商业试剂盒与血清总蛋白的相关性和偏差是可以接受的。因此,这些试剂盒可以在中国可靠地使用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号